Study summary
The phase 2b vaccine benefit held up over five years
49%lower risk of recurrence or death at 5 years
What was tested
Five-year follow-up of the phase 2b trial of intismeran autogene plus pembrolizumab against pembrolizumab alone after melanoma surgery.
What they found
- Risk of recurrence or death remained 49% lower (hazard ratio 0.51).
- Risk of distant spread or death was also lower.
What it means
Long-term support for the phase 3 result.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.